Radiopharm Theranostics Files 6-K for September 2025
Ticker: RDPTF · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer, sec-filing
TL;DR
Radiopharm Theranostics (RPTX) filed its monthly 6-K, standard reporting for foreign issuers.
AI Summary
Radiopharm Theranostics Limited, a foreign private issuer, filed a Form 6-K on September 30, 2025, for the month of September 2025. The company is based in Carlton, Victoria, Australia, and operates in the Pharmaceutical Preparations sector. This filing is made pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates ongoing reporting requirements for Radiopharm Theranostics as a foreign private issuer with the SEC, providing transparency to investors.
Risk Assessment
Risk Level: low — This is a routine reporting form for a foreign private issuer and does not contain specific financial or operational news that would inherently increase risk.
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 001-41621 (company) — SEC File Number
- 251357990 (company) — Film Number
- September 2025 (date) — Reporting Period
- 20250930 (date) — Filing Date
- Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (location) — Principal Executive Office
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to furnish information that the issuer makes public in its home country.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is September 30, 2025.
What is the reporting period for this Form 6-K?
The reporting period for this Form 6-K is the month of September 2025.
Where is Radiopharm Theranostics Limited's principal executive office located?
Radiopharm Theranostics Limited's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Does Radiopharm Theranostics file an annual report on Form 20-F or 40-F?
Yes, Radiopharm Theranostics indicates it files or will file annual reports under cover of Form 20-F.
Filing Stats: 318 words · 1 min read · ~1 pages · Grade level 19.3 · Accepted 2025-09-29 21:52:23
Filing Documents
- ea0259419-6k_radio.htm (6-K) — 12KB
- ea025941901ex99-1_radio.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001213900-25-093349.txt ( ) — 42KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on September 30, 2025 titled: - “Radiopharm Theranostics Partners with Starpharma on Research” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Radiopharm Theranostics Partners with Starpharma on Research 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: September 30, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3